georgeclerk
- BMO Capital Markets has started BioMarin Pharmaceutical (BMRN) at outperform, stating that investors are overplaying potential erosion of sales of flagship treatment Voxzogo (~46% upside based on Tuesday close).
- BioMarin currently trades at 0.68x 2026 PEG, lower than its peers’ 2.18x.
